Jump Financial LLC Cuts Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Jump Financial LLC lessened its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 72.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,363 shares of the medical technology company's stock after selling 124,852 shares during the period. Jump Financial LLC's holdings in Alphatec were worth $731,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Cerity Partners LLC bought a new position in Alphatec in the fourth quarter valued at approximately $28,451,000. abrdn plc boosted its position in shares of Alphatec by 276.7% during the third quarter. abrdn plc now owns 1,382,770 shares of the medical technology company's stock worth $17,935,000 after purchasing an additional 1,015,668 shares in the last quarter. Fred Alger Management LLC boosted its position in shares of Alphatec by 48.9% during the third quarter. Fred Alger Management LLC now owns 2,336,718 shares of the medical technology company's stock worth $30,307,000 after purchasing an additional 767,280 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Alphatec by 24.5% during the third quarter. American Century Companies Inc. now owns 2,655,328 shares of the medical technology company's stock worth $34,440,000 after purchasing an additional 523,323 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Alphatec by 193.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,293 shares of the medical technology company's stock worth $8,058,000 after purchasing an additional 409,701 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Stock Performance

Shares of Alphatec stock traded down $0.02 during trading on Monday, hitting $11.03. 1,543,533 shares of the stock were exchanged, compared to its average volume of 1,701,169. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.40 and a beta of 1.48. The company has a fifty day moving average price of $12.94 and a 200-day moving average price of $13.62. Alphatec Holdings, Inc. has a 1-year low of $8.66 and a 1-year high of $19.14. The company has a current ratio of 2.39, a quick ratio of 1.49 and a debt-to-equity ratio of 13.63.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $138.48 million for the quarter, compared to analyst estimates of $134.07 million. Alphatec had a negative return on equity of 1,767.81% and a negative net margin of 37.45%. The firm's revenue for the quarter was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.40) earnings per share. As a group, equities analysts predict that Alphatec Holdings, Inc. will post -1.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and set a $23.00 price target on shares of Alphatec in a research report on Wednesday, May 8th. Piper Sandler dropped their price objective on shares of Alphatec from $19.00 to $17.00 and set an "overweight" rating on the stock in a report on Wednesday, May 8th. Wells Fargo & Company assumed coverage on shares of Alphatec in a report on Friday, February 9th. They set an "overweight" rating and a $26.00 price objective on the stock. Canaccord Genuity Group restated a "buy" rating and set a $25.00 price objective on shares of Alphatec in a report on Wednesday, March 20th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a report on Monday, March 4th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Alphatec currently has an average rating of "Moderate Buy" and an average target price of $22.89.

Insider Buying and Selling

In related news, EVP David Sponsel sold 17,820 shares of Alphatec stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $15.34, for a total transaction of $273,358.80. Following the completion of the sale, the executive vice president now owns 654,661 shares of the company's stock, valued at approximately $10,042,499.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP David Sponsel sold 17,820 shares of Alphatec stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $15.34, for a total transaction of $273,358.80. Following the completion of the sale, the executive vice president now owns 654,661 shares of the company's stock, valued at approximately $10,042,499.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Scott Lish sold 11,963 shares of the business's stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $15.34, for a total transaction of $183,512.42. Following the completion of the sale, the chief operating officer now directly owns 538,240 shares of the company's stock, valued at approximately $8,256,601.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 282,569 shares of company stock valued at $3,931,095. Company insiders own 22.80% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.